Get Adobe Flash player
Rectal Cancer 21. 22. 23. 24. 25. 26. 27. 28. 29. 30. 31. 32. 33. 34. 35. 36. 37. 38. 39. 40. 30 excision for surgical treatment of rectal cancer, J Surg Oncol, 2000;74(1):21–3. Roh MS, Colangelo LH, O’Connell MJ, et al., Preoperative multimodality therapy improves disease-free survival in patients with carcinoma of the rectum: NSABP R-03, J Clin Oncol, 2009;27(31):5124–30. Sauer R, Liersch T, Merkel S, et al., Preoperative versus postoperative chemoradiotherapy for rectal cancer, N Engl J Med, 2004;351(17):1731–40. Park JH, Yoon SM, Yu CS, et al., Randomized phase 3 trial comparing preoperative and postoperative chemoradiotherapy with capecitabine for locally advanced rectal cancer, Cancer, 2011;117(16):3703–12. Jones WE 3rd, Thomas CR Jr, Herman JM, et al., ACR appropriateness criteria(R) resectable rectal cancer, Radiat Oncol, 2012;7:161. Sauer R, Liersch T, Merkel S, et al., Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years, J Clin Oncol, 2012;30(16):1926–33. O’Connell MJ, Martenson JA, Wieand HS, et al., Improving adjuvant therapy for rectal cancer by combining protracted- infusion fluorouracil with radiation therapy after curative surgery, N Engl J Med, 1994;331(8):502–7. Smalley SR, Benedetti JK, Williamson SK, et al., Phase III trial of fluorouracil-based chemotherapy regimens plus radiotherapy in postoperative adjuvant rectal cancer: GI INT 0144, J Clin Oncol, 2006;24(22):3542–7. Hofheinz R, Capecitabine (Cape) versus 5-fluorouracil (5-FU)-based (neo)adjuvant chemoradiotherapy (CRT) for locally advanced rectal cancer (LARC): Long-term results of a randomized, phase III trial, ASCO Meeting Abstracts, 2011;29(15_Suppl.):3504. Roh MS, The impact of capecitabine and oxaliplatin in the preoperative multimodality treatment in patients with carcinoma of the rectum: NSABP R-04, ASCO Meeting Abstracts, 2011;29(15_Suppl.):3503. Mohiuddin M, Mohiuddin MM, Neoadjuvant chemoradiation in rectal cancer: time to start in a new direction, J Clin Oncol, 2011;29(12):e350–1; author reply e352–3. Chon BH, Loeffler JS, The effect of nonmalignant systemic disease on tolerance to radiation therapy, Oncologist, 2002;7(2):136–43. Kapiteijn E, Marijnen CA, Nagtegaal ID, et al., Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer, N Engl J Med, 2001;345(9):638–46. Bujko K, Nowacki MP, Nasierowska-Guttmejer A, et al., Long- term results of a randomized trial comparing preoperative short-course radiotherapy with preoperative conventionally fractionated chemoradiation for rectal cancer, Br J Surg, 2006;93(10):1215–23. Ngan S, A randomized trial comparing local recurrence (LR) rates between short-course (SC) and long-course (LC) preoperative radiotherapy (RT) for clinical T3 rectal cancer: An intergroup trial (TROG, AGITG, CSSANZ, RACS), ASCO Meeting Abstracts, 2010;28(15_Suppl.):3509. Maas M, Nelemans PJ, Valentini V, et al., Long-term outcome in patients with a pathological complete response after chemoradiation for rectal cancer: a pooled analysis of individual patient data, Lancet Oncol, 2010;11(9):835–44. André T, Boni C, Navarro M, et al., Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer, N Engl J Med, 2004;350(23):2343–51. Kuebler JP, Colangelo L, O’Connell MJ, et al., Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07, J Clin Oncol, 2007;25(16):2198–204. Yothers G, O’Connell MJ, Allegra CJ, et al., Oxaliplatin as adjuvant therapy for colon cancer: updated results of NSABP C-07 trial, including survival and subset analyses, J Clin Oncol, 2011;29(28):3768–74. de Gramont A, Figer A, Seymour M, et al., Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer, J Clin Oncol, 2000;18(16):2938–47. Ducreux M, Malka D, Mendiboure J, et al., Sequential versus combination chemotherapy for the treatment of advanced colorectal cancer (FFCD 2000-05): an open-label, randomised, phase 3 trial, Lancet Oncol, 2011;12(11):1032–44. 41. 42. 43. 44. 45. 46. 47. 48. 49. 50. 51. 52. 53. 54. 55. 56. 57. 58. 59. Aschele C, Cionini L, Lonardi S, et al., Primary tumor response to preoperative chemoradiation with or without oxaliplatin in locally advanced rectal cancer: pathologic results of the STAR-01 randomized phase III trial, J Clin Oncol, 2011;29(20):2773–80. Gérard JP, Azria D, Gourgou-Bourgade S, et al., Clinical Outcome of the ACCORD 12/0405 PRODIGE 2 Randomized Trial in Rectal Cancer, J Clin Oncol, 2012;30(36):4558–65. Rödel C, Liersch T, Becker H, et al., Preoperative chemoradiotherapy and postoperative chemotherapy with fluorouracil and oxaliplatin versus fluorouracil alone in locally advanced rectal cancer: initial results of the German CAO/ARO/AIO-04 randomised phase 3 trial, Lancet Oncol, 2012;13(7):679–87. Willett CG, Duda DG, di Tomaso E, et al., Efficacy, safety, and biomarkers of neoadjuvant bevacizumab, radiation therapy, and fluorouracil in rectal cancer: a multidisciplinary phase II study, J Clin Oncol, 2009;27(18):3020–6. Crane CH, Eng C, Feig BW, et al., Phase II trial of neoadjuvant bevacizumab, capecitabine, and radiotherapy for locally advanced rectal cancer, Int J Radiat Oncol Biol Phys, 2010;76(3):824–30. Velenik V, Ocvirk J, Oblak I, Anderluh F, A phase II study of cetuximab, capecitabine and radiotherapy in neoadjuvant treatment of patients with locally advanced resectable rectal cancer, Eur J Surg Oncol, 2010;36(3):244–50. Horisberger K, Treschl A, Mai S, et al., Cetuximab in combination with capecitabine, irinotecan, and radiotherapy for patients with locally advanced rectal cancer: results of a Phase II MARGIT trial, Int J Radiat Oncol Biol Phys, 2009;74(5):1487–93. Dewdney A, Cunningham D, Tabernero J, et al., Multicenter randomized phase II clinical trial comparing neoadjuvant oxaliplatin, capecitabine, and preoperative radiotherapy with or without cetuximab followed by total mesorectal excision in patients with high-risk rectal cancer (EXPERT-C), J Clin Oncol, 2012. 30(14):1620–27. Navarro M, Dotor E, Rivera F, et al., A Phase II study of preoperative radiotherapy and concomitant weekly irinotecan in combination with protracted venous infusion 5-fluorouracil, for resectable locally advanced rectal cancer, Int J Radiat Oncol Biol Phys, 2006. 66(1):201–5. Willeke F, Horisberger K, Kraus-Tiefenbacher U, et al., A phase II study of capecitabine and irinotecan in combination with concurrent pelvic radiotherapy (CapIri-RT) as neoadjuvant treatment of locally advanced rectal cancer, Br J Cancer, 2007;96(6):912–17. Gollins S, Sun Myint A, Haylock B, et al., Preoperative chemoradiotherapy using concurrent capecitabine and irinotecan in magnetic resonance imaging-defined locally advanced rectal cancer: impact on long-term clinical outcomes, J Clin Oncol, 2011. 29(8):1042–9. Mohiuddin M, Winter K, Mitchell E, et al., Randomized phase II study of neoadjuvant combined-modality chemoradiation for distal rectal cancer: Radiation Therapy Oncology Group Trial 0012, J Clin Oncol, 2006;24(4):650–55. Van Cutsem E, Labianca R, Bodoky G, et al., Randomized phase III trial comparing biweekly infusional fluorouracil/leucovorin alone or with irinotecan in the adjuvant treatment of stage III colon cancer: PETACC-3, J Clin Oncol, 2009;27(19):3117–25. Saltz LB, Niedzwiecki D, Hollis D, et al., Irinotecan fluorouracil plus leucovorin is not superior to fluorouracil plus leucovorin alone as adjuvant treatment for stage III colon cancer: results of CALGB 89803, J Clin Oncol, 2007;25(23):3456–61. Ychou M, Raoul JL, Douillard JY, et al., A phase III randomised trial of LV5FU2 + irinotecan versus LV5FU2 alone in adjuvant high-risk colon cancer (FNCLCC Accord02/FFCD9802), Ann Oncol, 2009;20(4):674–80. Cercek A, Complete pathologic response in the primary of rectal or colon cancer treated with FOLFOX without radiation, ASCO Meeting Abstracts, 2010;28(15_Suppl.):3649. Schrag D, Neoadjuvant FOLFOX-bev, without radiation, for locally advanced rectal cancer, ASCO Meeting Abstracts, 2010;28(15_Suppl.):3511. Francois Y, Nemoz CJ, Baulieux J, et al., Influence of the interval between preoperative radiation therapy and surgery on downstaging and on the rate of sphincter-sparing surgery for rectal cancer: the Lyon R90-01 randomized trial, J Clin Oncol, 1999;17(8):2396. Tulchinsky H, Shmueli E, Figer A, et al., An interval >7 60. 61. 62. 63. 64. 65. 66. 67. 68. 69. 70. 71. 72. 73. 74. 75. 76. 77. 78. weeks between neoadjuvant therapy and surgery improves pathologic complete response and disease-free survival in patients with locally advanced rectal cancer, Ann Surg Oncol, 2008;15(10):2661–7. Moore HG, Gittleman AE, Minsky BD, et al., Rate of pathologic complete response with increased interval between preoperative combined modality therapy and rectal cancer resection, Dis Colon Rectum, 2004;47(3):279–86. Stein DE, Mahmoud NN, Anné PR, et al., Longer time interval between completion of neoadjuvant chemoradiation and surgical resection does not improve downstaging of rectal carcinoma, Dis Colon Rectum, 2003;46(4):448–53. Garcia-Aguilar J, Smith DD, Avila K, et al., Optimal timing of surgery after chemoradiation for advanced rectal cancer: preliminary results of a multicenter, nonrandomized phase II prospective trial, Ann Surg, 2011;254(1):97–102. Perez K, Pricolo V, Vrees M, et al., A phase II study of complete neoadjuvant therapy in rectal cancer (CONTRE): The Brown University Oncology Group, J Clin Oncol , 2012;30(Suppl. 34; abstract 335). Habr-Gama A, Perez RO, Nadalin W, et al., Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results, Ann Surg, 2004;240(4):711–17; discussion 717–18. Habr-Gama A, Perez RO, Proscurshim I, et al., Patterns of failure and survival for nonoperative treatment of stage c0 distal rectal cancer following neoadjuvant chemoradiation therapy, J Gastrointest Surg, 2006;10(10):1319–28; discussion 1328–9. Maas M, Beets-Tan RG, Lambregts DM, et al., Wait-and-see policy for clinical complete responders after chemoradiation for rectal cancer, J Clin Oncol, 2011;29(35):4633–40. Smith JD, Ruby JA, Goodman KA, et al., Nonoperative management of rectal cancer with complete clinical response after neoadjuvant therapy, Ann Surg, 2012;256(6):965–72. Hiotis SP, Weber SM, Cohen AM, et al., Assessing the predictive value of clinical complete response to neoadjuvant therapy for rectal cancer: an analysis of 488 patients, J Am Coll Surg, 2002;194(2):131–5; discussion 135–6. Stipa F, Zernecke A, Moore HG, et al., Residual mesorectal lymph node involvement following neoadjuvant combined- modality therapy: rationale for radical resection?, Ann Surg Oncol, 2004;11(2):187–91. Habr-Gama A, Perez RO, Wynn G, et al., Complete clinical response after neoadjuvant chemoradiation therapy for distal rectal cancer: characterization of clinical and endoscopic findings for standardization, Dis Colon Rectum, 2010;53(12):1692–8. Engin G, Sharifov R, Güral Z, et al., Can diffusion-weighted MRI determine complete responders after neoadjuvant chemoradiation for locally advanced rectal cancer?, Diagn Interv Radiol, 2012;18(6):574–81. Nasu K, Kuroki Y, Kuroki S, et al., Diffusion-weighted single shot echo planar imaging of colorectal cancer using a sensitivity-encoding technique, Jpn J Clin Oncol, 2004;34(10):620–6. Roth Y, Tichler T, Kostenich G, et al., High-b-value diffusion- weighted MR imaging for pretreatment prediction and early monitoring of tumor response to therapy in mice, Radiology, 2004;232(3):685–92. Song I, Kim SH, Lee SJ, et al., Value of diffusion-weighted imaging in the detection of viable tumour after neoadjuvant chemoradiation therapy in patients with locally advanced rectal cancer: comparison with T2 weighted and PET/CT imaging, Br J Radiol, 2012;85(1013):577–86. Dzik-Jurasz A, Domenig C, George M, et al., Diffusion MRI for prediction of response of rectal cancer to chemoradiation, Lancet, 2002;360(9329):307–8. Bökkerink GM, de Graaf EJ, Punt CJ, et al., The CARTS study: Chemoradiation therapy for rectal cancer in the distal rectum followed by organ-sparing transanal endoscopic microsurgery, BMC Surg, 2011;11:34. Yu SK, Deferral of rectal surgery following a continued response to preoperative chemoradiotherapy (Watch and Wait) study: A phase II multicenter study in the United Kingdom, ASCO Meeting Abstracts, 2011;29(4_Suppl.):489. Nissan A, Dangelica MI, Shoup MC, Hartley JE, Randomized clinical trials in rectal and anal cancer, Surg Oncol Clin N Am, 2002;11(1):149–72, ix. Oncology & H ematology Re view